Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Cardiotoxicity × oblimersen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1 Solid Tumors 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Melanoma 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Extensive Stage Small Cell Lung Cancer 1 Cardiotoxicity 1

Interventions

oblimersen 1 Razoxane 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Exercise 1 Doxorubicin 1 Dexrazoxane 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00039481 2013-01-17

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡